185 related articles for article (PubMed ID: 19401062)
1. Where are we with adjuvant therapy of stage III and IV melanoma in 2009?
Fecher LA; Flaherty KT
J Natl Compr Canc Netw; 2009 Mar; 7(3):295-304. PubMed ID: 19401062
[TBL] [Abstract][Full Text] [Related]
2. [Adjuvant interferon-alpha therapy of malignant melanoma. Position of the Dermatologic Oncology Working Group].
Hauschild A; Dummer R; Garbe C; Kaufmann R; Schadendorf D; Soyer HP; Stadler R; Tilgen W
Hautarzt; 1998 Mar; 49(3):167-9. PubMed ID: 9565782
[No Abstract] [Full Text] [Related]
3. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity.
Eggermont AM; Suciu S; Rutkowski P; Kruit WH; Punt CJ; Dummer R; Salès F; Keilholz U; de Schaetzen G; Testori A;
Eur J Cancer; 2016 Mar; 55():111-21. PubMed ID: 26790144
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant therapy for high-risk bulky regional melanoma.
Tarhini AA; Pahuja S; Kirkwood JM
J Surg Oncol; 2011 Sep; 104(4):386-90. PubMed ID: 21858833
[TBL] [Abstract][Full Text] [Related]
5. Interferon adjuvant therapy of melanoma.
Kirkwood JM; Wazer D; Rosenstein M
Cancer; 1997 May; 79(9):1843-6. PubMed ID: 9129006
[No Abstract] [Full Text] [Related]
6. [High-dose interferon-alpha and adjuvant treatment of melanoma with poor prognosis: requiem for a drug marketing license?].
Saiag P
Ann Dermatol Venereol; 1999 Mar; 126(3):211-3. PubMed ID: 10394432
[No Abstract] [Full Text] [Related]
7. The adjuvant treatment of malignant melanoma.
Reintgen D; Kirkwood J
J Fla Med Assoc; 1997 Mar; 84(3):147-52. PubMed ID: 9143164
[TBL] [Abstract][Full Text] [Related]
8. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma.
Grob JJ; Dreno B; de la Salmonière P; Delaunay M; Cupissol D; Guillot B; Souteyrand P; Sassolas B; Cesarini JP; Lionnet S; Lok C; Chastang C; Bonerandi JJ
Lancet; 1998 Jun; 351(9120):1905-10. PubMed ID: 9654256
[TBL] [Abstract][Full Text] [Related]
9. Melanoma adjuvant therapy.
Tarhini AA; Thalanayar PM
Hematol Oncol Clin North Am; 2014 Jun; 28(3):471-89. PubMed ID: 24880942
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of cutaneous melanoma].
Dummer R; Nestle FO; Hofbauer G; Böni R; Burg G
Ther Umsch; 1998 Aug; 55(8):509-14. PubMed ID: 9757818
[TBL] [Abstract][Full Text] [Related]
11. Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment.
Bramlette TB; Lawson DH; Washington CV; Veledar E; Johns BR; Brisman SF; Abramova L; Chen SC
Dermatol Surg; 2007 Jan; 33(1):11-6. PubMed ID: 17214673
[TBL] [Abstract][Full Text] [Related]
12. Rheumatoid arthritis complicating adjuvant interferon-alpha therapy for malignant melanoma.
Johnson DM; Hayat SQ; Burton GV
J Rheumatol; 1999 Apr; 26(4):1009-10. PubMed ID: 10229440
[No Abstract] [Full Text] [Related]
13. Advances in melanoma therapy.
Johnson TM; Yahanda AM; Chang AE; Fader DJ; Sondak VK
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):731-41. PubMed ID: 9591818
[TBL] [Abstract][Full Text] [Related]
14. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part I: Management of stage III disease.
Fox MC; Lao CD; Schwartz JL; Frohm ML; Bichakjian CK; Johnson TM
J Am Acad Dermatol; 2013 Jan; 68(1):1.e1-9; quiz 10-12. PubMed ID: 23244383
[TBL] [Abstract][Full Text] [Related]
15. Clinical prognostic factors in adjuvant melanoma trial.
Nathanson L
J Clin Oncol; 1996 Jun; 14(6):1967-8. PubMed ID: 8656271
[No Abstract] [Full Text] [Related]
16. [Cutaneous necrosis due to interferon alpha in a patient with melanoma].
Aguilar García G; Serrano Falcón C; Serrano Falcón Mdel M; Carmona MD; Linares Solano J; Serrano Ortega S
Actas Dermosifiliogr; 2006 Oct; 97(8):539-42. PubMed ID: 17067536
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant interferon alfa-2b for high-risk melanoma.
Retsas S
J Clin Oncol; 1996 Jun; 14(6):1968-9. PubMed ID: 8656272
[No Abstract] [Full Text] [Related]
18. Adjuvant therapy of malignant melanoma and the role of sentinel node mapping.
Eggermont AM
Recent Results Cancer Res; 2000; 157():178-89. PubMed ID: 10857171
[TBL] [Abstract][Full Text] [Related]
19. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant therapy for high-risk primary and resected metastatic melanoma.
Hersey P
Intern Med J; 2003; 33(1-2):33-43. PubMed ID: 12534876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
